T1	Participants 35 75	BRAF mutation in stage III colon cancer:
T2	Participants 211 237	colorectal carcinogenesis.
T3	Participants 448 485	patients with stage III colon cancer.
T4	Participants 561 649	506 stage III colon cancer patients enrolled in a randomized adjuvant chemotherapy trial
T5	Participants 959 983	75 BRAF-mutated patients
T6	Participants 1768 1791	stage III colon cancer.
